Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
PLoS Med ; 19(11): e1004107, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-36355774

RESUMO

BACKGROUND: Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization's Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies-those aligned with the WHO Unity protocol-were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 (p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence (p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. CONCLUSIONS: In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.


Assuntos
COVID-19 , SARS-CoV-2 , Criança , Adulto , Humanos , COVID-19/epidemiologia , Estudos Soroepidemiológicos , Estudos Transversais , Pandemias
2.
Risk Anal ; 41(12): 2240-2265, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-33998026

RESUMO

BACKGROUND: In Southeast Asia from 2004 to 2006, highly pathogenic avian influenza (HPAI) resulted in culling 45 million birds and jeopardizing sustainable agricultural production. HPAI is highly virulent; small-scale farms present a high-risk environment for disease transmission between animals and humans. We investigated how attitudes toward HPAI influence water-related biosecurity mitigation behaviors on small-scale farms in Vietnam using the conceptual framework Social Cognitive Theory. METHOD: We analyzed a secondary cross-sectional data set from northern (Thai Binh) and southern (An Giang) provinces in Vietnam, describing a stratified randomized selection of 600 small-scale farmers who were interviewed using questionnaires and in-person interviews. Logistic regression analysis and odds ratios were used to examine relationships between factors influencing HPAI attitudes, social norms, perceived importance, and behaviors (α = 0.10) RESULTS: Concern about the severity of HPAI was significantly associated with increased perceived importance for all water management biosecurity methods (p < 0.01). Media and/or peer influence had negative effects on perceived importance to practice water-related biosecurity (p < 0.10). High importance of practice water-related biosecurity resulted in high uptake (p < 0.05). Past experiences with HPAI were significant in predicting perceived importance; none were significant in describing behavior uptake. DISCUSSION: Biosecurity guidelines may not be consistent with management styles of Vietnamese small-scale farms; perceived importance of a behavior may be an important mediating variable. Gaps exist in uptake of water management practices as biosecurity for HPAI, potentially negatively affected by peer and media influence. Our results should be of interest to public health and policy authorities addressing HPAI mitigation.


Assuntos
Atitude , Comportamento , Biosseguridade , Fazendeiros/psicologia , Influenza Aviária/prevenção & controle , Percepção , Água , Animais , Aves , Estudos Transversais , Conjuntos de Dados como Assunto , Fazendeiros/estatística & dados numéricos , Feminino , Humanos , Masculino , Saúde Pública , População Rural , Inquéritos e Questionários , Vietnã
3.
Influenza Other Respir Viruses ; 17(8): e13170, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37621920

RESUMO

The WHO Unity Studies initiative engaged low- and middle-income countries in the implementation of standardised SARS-CoV-2 sero-epidemiological investigation protocols and timely sharing of comparable results for evidence-based action. To gain a deeper understanding of the methodological challenges faced when conducting seroprevalence studies in the African region, we conducted unstructured interviews with key study teams in five countries. We discuss the challenges identified: participant recruitment and retention, sampling, sample and data management, data analysis and presentation. Potential solutions to aid future implementation include preparedness actions such as the development of new tools, robust planning and practice.


Assuntos
COVID-19 , Humanos , COVID-19/epidemiologia , COVID-19/prevenção & controle , SARS-CoV-2 , Estudos Soroepidemiológicos , África/epidemiologia
4.
Vaccines (Basel) ; 10(12)2022 Nov 24.
Artigo em Inglês | MEDLINE | ID: mdl-36560415

RESUMO

Background: Many serological assays to detect SARS-CoV-2 antibodies were developed during the COVID-19 pandemic. Differences in the detection mechanism of SARS-CoV-2 serological assays limited the comparability of seroprevalence estimates for populations being tested. Methods: We conducted a systematic review and meta-analysis of serological assays used in SARS-CoV-2 population seroprevalence surveys, searching for published articles, preprints, institutional sources, and grey literature between 1 January 2020, and 19 November 2021. We described features of all identified assays and mapped performance metrics by the manufacturers, third-party head-to-head, and independent group evaluations. We compared the reported assay performance by evaluation source with a mixed-effect beta regression model. A simulation was run to quantify how biased assay performance affects population seroprevalence estimates with test adjustment. Results: Among 1807 included serosurveys, 192 distinctive commercial assays and 380 self-developed assays were identified. According to manufacturers, 28.6% of all commercial assays met WHO criteria for emergency use (sensitivity [Sn.] >= 90.0%, specificity [Sp.] >= 97.0%). However, manufacturers overstated the absolute values of Sn. of commercial assays by 1.0% [0.1, 1.4%] and 3.3% [2.7, 3.4%], and Sp. by 0.9% [0.9, 0.9%] and 0.2% [−0.1, 0.4%] compared to third-party and independent evaluations, respectively. Reported performance data was not sufficient to support a similar analysis for self-developed assays. Simulations indicate that inaccurate Sn. and Sp. can bias seroprevalence estimates adjusted for assay performance; the error level changes with the background seroprevalence. Conclusions: The Sn. and Sp. of the serological assay are not fixed properties, but varying features depending on the testing population. To achieve precise population estimates and to ensure the comparability of seroprevalence, serosurveys should select assays with high performance validated not only by their manufacturers and adjust seroprevalence estimates based on assured performance data. More investigation should be directed to consolidating the performance of self-developed assays.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA